THERAtRAME builds first-in-class tRNA drugs for the patients today’s cancer therapies can’t reach
THERAtRAME builds first-in-class tRNA drugs for the patients today’s cancer therapies can’t reach. The company is developing first-in-class oncology therapies by inhibiting tRNA-modifying enzymes, a largely untapped yet highly transformative space in cancer biology.